Johnson & Johnson (JNJ): Notes From Management Meetings - UBS

September 28, 2016 8:29 AM EDT
Get Alerts JNJ Hot Sheet
Price: $115.70 +1.00%

Rating Summary:
    10 Buy, 15 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 25 | Down: 28 | New: 8
Trade JNJ Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

UBS analyst, Matt Miksic, reiterated his Buy rating on shares of Johnson & Johnson (NYSE: JNJ) after a series of meetings with management in Zurich and Geneva. The company reviewed the strategy and opportunities behind its recently announced AMO acquisition, and the growth drivers and investment opportunities across its three major businesses.

The analyst was encouraged that, despite the pending deployment of cash for AMO, the company remains committed to putting its $30-35 bil in excess capital to work in a disciplined fashion to enhance shareholder value.

No change to the price target of $137.

For an analyst ratings summary and ratings history on Johnson & Johnson click here. For more ratings news on Johnson & Johnson click here.

Shares of Johnson & Johnson closed at $119.22 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

UBS, Definitive Agreement

Add Your Comment